NuVasive (NASDAQ:NUVA) & USA Equities (OTCMKTS:USAQ) Head to Head Contrast

NuVasive (NASDAQ:NUVAGet Rating) and USA Equities (OTCMKTS:USAQGet Rating) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, institutional ownership, valuation, profitability, analyst recommendations, earnings and dividends.

Earnings & Valuation

This table compares NuVasive and USA Equities’ gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
NuVasive $1.14 billion 2.61 -$64.09 million ($1.25) -45.85
USA Equities $1.41 million 2.95 -$770,000.00 N/A N/A

USA Equities has lower revenue, but higher earnings than NuVasive.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for NuVasive and USA Equities, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
NuVasive 1 4 7 0 2.50
USA Equities 0 0 1 0 3.00

NuVasive currently has a consensus target price of $65.40, indicating a potential upside of 14.12%. Given NuVasive’s higher probable upside, equities research analysts plainly believe NuVasive is more favorable than USA Equities.

Insider & Institutional Ownership

98.1% of NuVasive shares are held by institutional investors. 0.5% of NuVasive shares are held by company insiders. Comparatively, 74.2% of USA Equities shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Volatility & Risk

NuVasive has a beta of 1.14, suggesting that its share price is 14% more volatile than the S&P 500. Comparatively, USA Equities has a beta of -2.28, suggesting that its share price is 328% less volatile than the S&P 500.


This table compares NuVasive and USA Equities’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
NuVasive -5.63% 10.65% 4.08%
USA Equities -54.39% -0.53% -0.13%


NuVasive beats USA Equities on 8 of the 12 factors compared between the two stocks.

About NuVasive (Get Rating)

NuVasive, Inc., a medical technology company, develops, manufactures, and sells procedural solutions for spine surgery. It provides surgical access instruments, including Maxcess integrated split-blade retractor system that enable less-invasive surgical techniques by minimizing soft tissue disruption during spine surgery; specialized spinal implants to advance spinal fusion by enhancing the osseointegration and biomechanical properties of implant materials, including porous titanium and porous polyetheretherketone; and fixation system that facilitates the preservation and restoration of patient alignment. The company also offers cervical total disc replacement technology for cervical spinal fusion surgery; neuromonitoring systems, which use proprietary software-driven nerve detection and avoidance technology, and its intraoperative neuromonitoring services and support; and Pulse platform, a software ecosystem that integrates multiple hardware technologies into a single, condensed footprint in the operating room. In addition, it provides expandable growing rod implant systems for the treatment of early-onset scoliosis; various biologics that are used to aid in the spinal fusion or bone healing process; Precice, an intramedullary implant device that utilizes the MAGEC technology to non-invasively lengthen the femur and tibia; and onsite and remote monitoring of the neurological systems of patients undergoing spinal and brain-related surgeries. The company sells its products to patients, surgeons, hospitals, and insurers through independent sales agents, directly employed sales personnel, and distributors in the United States and internationally. NuVasive, Inc. was incorporated in 1997 and is headquartered in San Diego, California.

About USA Equities (Get Rating)

USA Equities Corp., a medical device technology and software as a service (SaaS) company focuses on value-based healthcare, informatics, and algorithmic personalized medicine. It also develops digital therapeutics and point of care solutions to support remote patient monitoring, address chronic care, and preventive medicine. In addition, the company provides quality health score lab expert system (QHSLab), a cloud-based SaaS system, which provides physicians and healthcare organizations with the ability to capture and store patient information electronically in a secure database; and distributes AllergiEnd, a diagnostic related product and allergen immunotherapy treatments to primary care physicians. Its products are designed to promote prevention, early detection, management, and reversal of chronic diseases. The company was formerly known as American Biogenetic Sciences, Inc. and changed its name to USA Equities Corp. in May 2015. USA Equities Corp. was incorporated in 1983 and is based in West Palm Beach, Florida.

Receive News & Ratings for NuVasive Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for NuVasive and related companies with’s FREE daily email newsletter.


Leave a Reply

Your email address will not be published. Required fields are marked *